Protagonist Therapeutics Inc. (PTGX)

factsheet Factsheet
  • Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $1,771 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-106 Mln

Protagonist Therapeutics Inc. (PTGX) Share Price

$30.38

As on 29-Feb-2024 16:01 EST

up-down-arrow $-0.05-0.16%

  • Prev Close info

    $30.43

  • Day's Openinfo

    $31.00

  • Today's Highinfo

    $31.32

  • Today's Lowinfo

    $30.13

  • Today's Volumeinfo

    673,489

  • 52 Week rangeinfo

    $13.72 - 31.40

Please wait...

Protagonist Therapeutics Inc. (PTGX) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Protagonist Therapeutics (PTGX)
32.49 21.86 73.40 86.72 8.83 29.66 --
S&P BSE Sensex*
2.08 2.78 10.09 25.07 14.52 15.51 13.32
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 29-Feb-2024  |  *As on 01-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Protagonist Therapeutics (PTGX)
110.17 -68.10 69.64 185.96 4.75 -67.44 -5.41
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Protagonist Therapeutics Inc. (PTGX) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Protagonist Therapeutics Inc. (PTGX)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Protagonist Therapeutics Inc. (PTGX)

        CEO, President, Secretary & Director

        Dr. Dinesh V. Patel Ph.D.

        Chief Development Officer

        Dr. Suneel K. Gupta Ph.D.

        Headquarters

        Newark, CA

        FAQs for Protagonist Therapeutics Inc. (PTGX)

        The total asset value of Protagonist Therapeutics Inc. (PTGX) stood at $ 358 Mln as on 30-Sep-23

        The share price of Protagonist Therapeutics Inc. (PTGX) is $30.38 (NASDAQ) as of 29-Feb-2024 16:01 EST. Protagonist Therapeutics Inc. (PTGX) has given a return of 8.83% in the last 3 years.

        Protagonist Therapeutics Inc. (PTGX) has a market capitalisation of $ 1,771 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Protagonist Therapeutics Inc. (PTGX) is 5.81 times as on 29-Feb-2024, a 0.95% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Protagonist Therapeutics Inc. (PTGX) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Protagonist Therapeutics Inc. (PTGX) and enter the required number of quantities and click on buy to purchase the shares of Protagonist Therapeutics Inc. (PTGX).

        Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160

        The CEO & director of Dr. Dinesh V. Patel Ph.D.. is Protagonist Therapeutics Inc. (PTGX), and CFO & Sr. VP is Dr. Suneel K. Gupta Ph.D..

        The promoters of Protagonist Therapeutics Inc. (PTGX) have pledged 0% of the total equity as on Sep-23.

        Protagonist Therapeutics Inc. (PTGX) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Protagonist Therapeutics Inc. (PTGX) was $-106 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $1,770.95 Mln
        • Revenue (TTM)revenue-information $0.00 Mln
        • Earnings (TTM) earning-information $-106.38 Mln
        • Cash date-information $320.75 Mln
        • Total Debt info $1.80 Mln
        • Insider's Holding 1.82%
        • Liquidity liquidity High
        • 52 Week range week-range $13.72 - 31.40
        • Shares outstanding share-outstanding 57,678,100
        • 10 Years Aggregate:

          CFO: $-547.02 Mln

          EBITDA: $-523.86 Mln

          Net Profit: $-668.85 Mln

        About The Company

        • IPO Date 11-Aug-2016
        • CEO, President, Secretary & Director Dr. Dinesh V. Patel Ph.D.
        • Chief Development Officer Dr. Suneel K. Gupta Ph.D.
        • Listing key-listing NASDAQ: PTGX
        • Country United States
        • Headquarters headquarters Newark, CA
        • Website website https://www.protagonist-inc.com
        • Business

          Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that...  completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. Address: 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160  Read more

        share-fund-plan-icon